Welcome and Introduction to the IPC and SOLAPSO
Angela Londoño, MSc, MD, Colombia
Fernando Valenzuela, MD, Chile
Infections and Anti TNF
Fernando Valenzuela, MD, Chile
Infections and Anti ILs
Cristina Echeverría, MD, Argentina
TB and Psoriasis Treatments
Ricardo Romitii, MD, PhD, Brazil
Infections and New Small Molecules
Angela Londoño, MSc, MD, Colombia
Clinical Cases and LATAM Challenges – Panel Discussion
Giuliana Castro Vargas, MD, Peru
Enrique Loayza, MD, Ecuador
Closing Remarks
Angela Londoño, MSc, MD, Colombia
Fernando Valenzuela, MD, Chile
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
